OPTIMIZING COLORECTAL CANCER CARE WITH GENETICALLY-GUIDED DOSING OF 5-FLUOROURACIL AND IRINOTECAN: THE VALUE OF REDUCING UNCERTAINTY

Rivers Zachary; Stenehjem David; Kuntz Karen M.

首页> 外文期刊>Medical decision making: An international journal of the Society for Medical Decision Making >OPTIMIZING COLORECTAL CANCER CARE WITH GENETICALLY-GUIDED DOSING OF 5-FLUOROURACIL AND IRINOTECAN: THE VALUE OF REDUCING UNCERTAINTY

【24h】

OPTIMIZING COLORECTAL CANCER CARE WITH GENETICALLY-GUIDED DOSING OF 5-FLUOROURACIL AND IRINOTECAN: THE VALUE OF REDUCING UNCERTAINTY

机译：用遗传导向剂量的5-氟尿嘧啶和Irinotecan优化结肠直肠癌护理：减少不确定性的价值

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Medical decision making: An international journal of the Society for Medical Decision Making》 |2021年第4期|共1页
作者
Rivers Zachary; Stenehjem David; Kuntz Karen M.;
展开▼
作者单位

Univ Minnesota Coll Pharm Minneapolis MN 55455 USA;

Univ Minnesota Coll Pharm Duluth MN 55812 USA;

Univ Minnesota Sch Publ Hlth Div Hlth Policy &

Management Minneapolis MN USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类保健组织与事业（卫生事业管理）;
关键词
入库时间 2022-08-20 18:21:45

相似文献

外文文献
中文文献
专利

1. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer： a meta-analysis [J] . LIANG Xiao-bo, HOU Sheng-huai, Li Yao-ping, 中华医学杂志：英文版 . 2010,第022期
2. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis [J] . LIANG Xiao-bo, HOU Sheng-huai, Li Yao-ping, 中华医学杂志（英文版） . 2010,第022期
3. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer： A pilot study [J] . Francois Ghiringhelli, Boris Guiu, Bruno Chauffert, 世界胃肠病学杂志：英文版 . 2009,第034期
4. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study [J] . E. Aranda1* M. Valladares2 M. Martinez-Villacampa3 M. Benavides4 A. Gomez1 B. Massutti5 E. Marcuello6 M. Constenla7 J. C. Cámara8 A. Carrato9 R. Dueñas10 M. Reboredo2 M. Navarro3 and E. Díaz-Rubio11 Annals of Oncology . 2009,第2期

机译：每周伊立替康联合大剂量5-氟尿嘧啶（FUIRI）与两周一次伊立替康联合5-氟尿嘧啶/亚叶酸钙（FOLFIRI）作为转移性结直肠癌患者的一线化疗的随机研究：西班牙合作治疗消化道肿瘤研究小组
5. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting [J] . LuC.-Y., HuangC.-W., HuH.-M., Translational research: the journal of laboratory and clinical medicine . 2014,第2期

机译：在第一线治疗中，以贝伐单抗联合5-氟尿嘧啶/亚叶酸钙与伊立替康联合治疗的转移性结直肠癌患者，根据尿苷二磷酸尿苷二磷酸葡萄糖醛酸糖基转移酶1A1（UGT1A1）基因分型，提高伊立替康的预后优势
6. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9 [J] . Stine Braendegaard Winther, Pia ?sterlund, ?ke Berglund, BMC Cancer . 2017,第1期

机译：随机研究比较全剂量单药治疗（S-1，然后伊立替康）和降低剂量联合治疗（S-1 /奥沙利铂，然后S-1 /伊立替康）作为老年转移性大肠癌患者的初始治疗：NORDIC 9
7. Correlation study of (IL-17 , IL-17RA ) and some biochemical parameters with patients of iraq colorectal cancer after and before taking a dose of chemotherapy [C] . Mezher N. Moslem, A. F. Altaie International Conference on Materials Engineering and Science . 2020

机译：（IL-17，IL-17RA）与一些生物化学参数与伊拉克结肠直肠癌患者服用化疗的相关性研究
8. Use and outcomes of newer chemotherapeutic agents in colorectal cancer patients using Irinotecan as a case study. [D] . Obeidat, Nour A. 2008

机译：以伊立替康为例的结直肠癌患者中新型化疗药物的使用和结果。
9. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9 [O] . Stine Braendegaard Winther, Pia Österlund, Åke Berglund, 2017

机译：随机研究比较全剂量单一疗法（S-1伊立替康）和减量联合疗法（S-1 /奥沙利铂S-1 /伊立替康）作为老年转移性大肠癌患者的初始疗法：NORDIC 9
10. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer : NORDIC 9 [O] . Winther, Stine Braendegaard, Österlund, Pia, Berglund, Åke, 2017

机译：随机研究比较了全剂量单药治疗（S-1，然后伊立替康）和减剂量联合治疗（S-1 /奥沙利铂，然后S-1 /伊立替康）作为老年转移性大肠癌患者的初始治疗的方法：NORDIC 9
11. Health Care Systems for Tracking Colorectal Cancer Screening Tests: Final Report on the System Approach to Tracking and Increasing Screening for Public Health Improvement of Colorectal Cancer (SATIS-PH/CRC) Intervention [R] . Harris, D. M., Borksy, A. E. 2010

机译：用于跟踪结肠直肠癌筛查测试的医疗保健系统：跟踪和增加结直肠癌公共卫生改善筛查系统方法的最终报告（saTIs-pH / CRC）干预

OPTIMIZING COLORECTAL CANCER CARE WITH GENETICALLY-GUIDED DOSING OF 5-FLUOROURACIL AND IRINOTECAN: THE VALUE OF REDUCING UNCERTAINTY

著录项

相似文献

相关主题

期刊订阅